Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castrate Sensitive Prostate Cancer”

176 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 176 results

Not applicableStudy completedNCT01366053
What this trial is testing

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Who this might be right for
Prostate Cancer
CMX Research 125
Not applicableStudy completedNCT06498921
What this trial is testing

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 106
Not applicableActive Not RecruitingNCT05901649
What this trial is testing

The Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Janssen-Cilag Ltd. 504
Testing effectiveness (Phase 2)Active Not RecruitingNCT06734130
What this trial is testing

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06134271
What this trial is testing

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Jianbin Bi 160
Testing effectiveness (Phase 2)WithdrawnNCT05705700
What this trial is testing

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Who this might be right for
Prostate Cancer
Masonic Cancer Center, University of Minnesota
Not applicableUnknownNCT05161728
What this trial is testing

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Roderick van den Bergh 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT05067140
What this trial is testing

ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Novartis Pharmaceuticals 152
Not applicableLooking for participantsNCT07146113
What this trial is testing

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Who this might be right for
Prostate Cancer
AstraZeneca 400
Large-scale testing (Phase 3)Looking for participantsNCT06177015
What this trial is testing

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Who this might be right for
Metastatic Prostate CancerIntermitent Anti-androgen Therapy
The First Affiliated Hospital with Nanjing Medical University 200
Not applicableLooking for participantsNCT07406282
What this trial is testing

Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-Sensitive Prostate Cancer
Bayer 1,400
Early research (Phase 1)Not Yet RecruitingNCT06099990
What this trial is testing

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd. 660
Testing effectiveness (Phase 2)Active Not RecruitingNCT03860987
What this trial is testing

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Who this might be right for
Castrate Sensitive Prostate Cancer
National Cancer Institute (NCI) 12
Not applicableStudy completedNCT06072196
What this trial is testing

Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Prostatic Neoplasms
Pfizer 3,017
Very early researchActive Not RecruitingNCT03511196
What this trial is testing

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Who this might be right for
Prostate CancerStage IV Prostate CancerAdvanced Prostate Cancer+1 more
H. Lee Moffitt Cancer Center and Research Institute 17
Not applicableActive Not RecruitingNCT06010914
What this trial is testing

Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 100
Post-approval studies (Phase 4)Study completedNCT00219219
What this trial is testing

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

Who this might be right for
Prostate Cancer
Novartis
Large-scale testing (Phase 3)Active Not RecruitingNCT02319837
What this trial is testing

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Who this might be right for
Hormone Sensitive Prostate CancerProstate CancerCancer of the Prostate
Pfizer 1,068
Not applicableStudy completedNCT05701007
What this trial is testing

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pfizer 1,083
Post-approval studies (Phase 4)Active Not RecruitingNCT06479187
What this trial is testing

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerMetastatic Hormone-sensitive Prostate Cancer (mHSPC)
Brigham and Women's Hospital 20
Load More Results